Literature DB >> 1651370

Molecular level model for the agonist/antagonist selectivity of the 1,4-dihydropyridine calcium channel receptor.

D A Langs1, Y W Kwon, P D Strong, D J Triggle.   

Abstract

Crystal structures of the 1,4-dihydropyridine (1,4-DHP) calcium channel activators Bay K 8643 [methyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(3-nitrophenyl)-pyridine-5-carboxy lat e], Bay O 8495 [methyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(3-trifluoromethylphenyl)-pyridine-5- carboxylate], and Bay O 9507 [methyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(4-nitrophenyl)-pyridine-5-carboxy lat e] were determined. The conformations of the 1,4-DHP rings of these activator analogues of Bay K 8644 [methyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(2-trifluoromethylphenyl)-pyridine-5- carboxylate] do not suggest that their activator properties are as strongly correlated with the degree of 1,4-DHP ring flattening as was indicated for members of the corresponding antagonist series. The solid state hydrogen bonding of the N(1)-H groups of the activators is not, unlike that of their antagonist counterparts, to acceptors that are directly in line with the donor. Rather, acceptor groups are positioned within +/- 60 degrees of the N(1)-H bond in the vertical plane of the 1,4-DHP ring. Previously determined structure-activity relationships have indicated the importance of this N(1)-H group to the activity of the 1,4-DHP antagonists. Based on these observations, a model is advanced to describe the 1,4-DHP binding site of the voltage-gated Ca2+ channel and its ability to accommodate both antagonist and activator ligands.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1651370     DOI: 10.1007/bf00129749

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  23 in total

1.  Molecular model of the action potential sodium channel.

Authors:  H R Guy; P Seetharamulu
Journal:  Proc Natl Acad Sci U S A       Date:  1986-01       Impact factor: 11.205

2.  Conformational features of calcium channel agonist and antagonist analogs of nifedipine.

Authors:  D A Langs; D J Triggle
Journal:  Mol Pharmacol       Date:  1985-05       Impact factor: 4.436

3.  Crystal structures and pharmacologic activities of 1,4-dihydropyridine calcium channel antagonists of the isobutyl methyl 2,6-dimethyl-4-(substituted phenyl)-1,4-dihydropyridine-3,5-dicarboxylate (nisoldipine) series.

Authors:  R Fossheim; A Joslyn; A J Solo; E Luchowski; A Rutledge; D J Triggle
Journal:  J Med Chem       Date:  1988-02       Impact factor: 7.446

Review 4.  Structure and function of voltage-sensitive ion channels.

Authors:  W A Catterall
Journal:  Science       Date:  1988-10-07       Impact factor: 47.728

5.  Structure-activity studies on nifedipine in isolated cardiac muscle.

Authors:  R Rodenkirchen; R Bayer; R Steiner; F Bossert; H Meyer; E Möller
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-12       Impact factor: 3.000

6.  Specific binding of a calcium channel activator, [3H]BAY k 8644, to membranes from cardiac muscle and brain.

Authors:  R A Janis; D Rampe; J G Sarmiento; D J Triggle
Journal:  Biochem Biophys Res Commun       Date:  1984-05-31       Impact factor: 3.575

7.  Receptor model for the molecular basis of tissue selectivity of 1, 4-dihydropyridine calcium channel drugs.

Authors:  D A Langs; P D Strong; D J Triggle
Journal:  J Comput Aided Mol Des       Date:  1990-09       Impact factor: 3.686

8.  Crystal structures of calcium channel antagonists: 2,6-dimethyl-3,5-dicarbomethoxy-4-[2-nitro-, 3-cyano-, 4-(dimethylamino)-, and 2,3,4,5,6-pentafluorophenyl]-1,4-dihydropyridine.

Authors:  A M Triggle; E Shefter; D J Triggle
Journal:  J Med Chem       Date:  1980-12       Impact factor: 7.446

9.  Stereoselectivity at the calcium channel: opposite action of the enantiomers of a 1,4-dihydropyridine.

Authors:  R P Hof; U T Rüegg; A Hof; A Vogel
Journal:  J Cardiovasc Pharmacol       Date:  1985 Jul-Aug       Impact factor: 3.105

10.  The enantiomers of the dihydropyridine derivative H 160/51 show opposite effects of stimulation and inhibition.

Authors:  P Gjörstrup; H Hårding; R Isaksson; C Westerlund
Journal:  Eur J Pharmacol       Date:  1986-04-02       Impact factor: 4.432

View more
  1 in total

1.  Nitric oxide, a possible mediator of 1,4-dihydropyridine-induced photorelaxation of vascular smooth muscle.

Authors:  F Lovren; S K O'Neill; D Bieger; N Igbal; E E Knaus; C R Triggle
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.